-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say. Read more…
Recent articles
Get the latest Long COVID news and commentary
Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
Check out our weekly podcast, Still Here
Spotify
Apple Podcasts
PocketCasts
iHeartRadio
RSS
Policy & Advocacy
Science
Covid-19
Health
-
Covid-19 reinfections are further disabling people with Long Covid
-
A win for healthcare workers and patients: The CDC returns HICPAC’s draft recommendations on infection control
-
This artist is memorializing the Covid-19 pandemic through textiles, and you can help
-
What recovery? Long Covid’s deep impact on Latinos
-
New CDC data identify more than 5,000 Long Covid deaths, but tally is likely a significant undercount
-
HHS gave million-dollar grants to nine Long Covid clinics; here’s how they plan to use the funding
-
Avoiding caregiver burnout: Wisdom for the ME and Long COVID community
-
How volunteering to become a lab rat paid off
-
COVID-19 triggered a life-threatening pulmonary embolism that led to long-term lung damage. It took two ER trips before doctors believed me.
-
Letter to the editors: The University of Washington’s Long COVID clinic